Screening for NAFLD using FibroScan

The medical staff in our hospital who volunteered for the NAFLD study using FibroScan (502 Touch, Echosens, France) were recruited at the time of the annual physical checkup between January and March 2018. Information about the study participants was collected including previous medical history, drinking, and smoking status. Those with chronic liver diseases, including viral hepatitis B or C, autoimmune liver disease, recent infections, prolonged use of steroids, or estrogens were excluded. Individuals with daily alcohol consumption >20 g (for males) or >10 g (for females) were not included. Subjects with alanine transaminase (ALT) or aspartate transaminase (AST) higher than 5 times or plasma creatinine level higher than 2 times the upper normal limit were also excluded from the analysis. The study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sen University [Ethics Committee Review (2016) No. 146]. Informed consent was obtained from each participant.

Free full text: Click here

Huang Z., Ng K., Chen H., Deng W, & Li Y. (2022). Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. Frontiers in Endocrinology, 12, 739875.

Publication 2021

FibroScan (502 Touch,

Alanine transaminase Aspartate transaminase Autoimmune disease Creatinine Estrogens Ethics committee Females Hospital ethics committee Hospital medical staff Infections Liver Liver disease Males Nafld Physical Plasma Steroids Touch Viral hepatitis b

Corresponding Organization : The First Affiliated Hospital, Sun Yat-sen University

Other organizations : Hospital Conde S. Januário, Panyu Hospital of Chinese Medicine

Top 5 similar protocols

Protocol cited in 3 other protocols

Variable analysis

independent variables

None explicitly mentioned

dependent variables

Liver fibrosis assessed by FibroScan (502 Touch, Echosens, France)

control variables

Exclusion of individuals with chronic liver diseases, including viral hepatitis B or C, autoimmune liver disease, recent infections, prolonged use of steroids, or estrogens
Exclusion of individuals with daily alcohol consumption >20 g (for males) or >10 g (for females)
Exclusion of individuals with alanine transaminase (ALT) or aspartate transaminase (AST) higher than 5 times or plasma creatinine level higher than 2 times the upper normal limit

positive controls

None explicitly mentioned

negative controls

None explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!